Haemonetics Corporation
Health
Performance
6.7
Risk
Sell
Buy
Curious about the Scores? Learn more.

Haemonetics Corporation stock rating and score history

All changes in ratings, performance and outlook tracked over time.

05.06.2026
Shaky at first, now slowly moving toward steady ground.
23.05.2026
Slight bounce. Could be noise – or a comeback brewing.
19.05.2026
Off life support. Still risky, but slightly less scary.
03.05.2026
Health’s picking up. Numbers look cleaner, cash flow tighter.
HAE
Haemonetics Corporation
71.28
+2.05%
6.7
Sell
Buy
Haemonetics Corporation

Haemonetics Corporation stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Haemonetics Corporation do? Business model and key facts

Get the full picture of Haemonetics Corporation: what it builds, where it operates, and how it makes money.

Haemonetics Corporation Profile

Sector: Healthcare

Industry: Medical - Instruments & Supplies

Employees (FY): 3657

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

shop
Company facts
Christopher A. Simon
CEO
3657
Employees worldwide
shop
Performance
1.25%
Last 12 months
26.36%
Last 5 years
shop
Growth
$1,36B
Revenue year
$167,68M
Net income
shop
Valuation
$3,08B
Market Cap
18.97
Price/Earnings Ratio

Stocks related to Haemonetics Corporation

Selected based on industry alignment and relative market positioning.

ICUI
ICU Medical, Inc.
136.61
+1.25%
5.0
Sell
Buy
ICU Medical, Inc.
MMSI
Merit Medical Systems, Inc.
64.48
+2.28%
7.0
Sell
Buy
Merit Medical Systems, Inc.
STVN
Stevanato Group S.p.A.
18.46
-0.27%
7.7
Sell
Buy
Stevanato Group S.p.A.
WRBY
Warby Parker Inc.
22.72
-5.80%
8.2
Sell
Buy
Warby Parker Inc.
LMAT
LeMaitre Vascular, Inc.
94.48
+0.98%
5.1
Sell
Buy
LeMaitre Vascular, Inc.

Events and news impacting Haemonetics Corporation stock

Earnings, coporate decisions and industry developments that can affect the share price.

Haemonetics Corporation fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.